AQR Arbitrage’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-71,760
Closed -$712K 1257
2021
Q3
$712K Buy
71,760
+54,260
+310% +$539K 0.02% 548
2021
Q2
$174K Hold
17,500
﹤0.01% 786
2021
Q1
$174K Sell
17,500
-7,500
-30% -$79.9K 0.01% 783
2020
Q4
$270K Hold
25,000
0.01% 866
2020
Q3
$259K Hold
25,000
0.01% 475
2020
Q2
$250K Buy
+25,000
New +$249K 0.01% 427

Other funds holding STLN

AQR Arbitrage's STLN Position: Q4 2021 in Review

AQR Arbitrage sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 71,760 shares — an estimated $712K sold.

AQR Arbitrage first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $712K in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • AQR Arbitrage reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • AQR Arbitrage sold 71,760 Starling Oncology shares in Q4 2021, an estimated $712K.
  • AQR Arbitrage first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
  • AQR Arbitrage's Starling Oncology position peaked at $712K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on AQR Arbitrage's 13F filing for Q4 2021, filed 14 Feb 2022.